Mulberry Leaf DNJ 100mg 12 Weeks: Postprandial Glucose -32%, Alpha-Glucosidase Block RCT
WELLNESS

Mulberry Leaf DNJ 100mg 12 Weeks: Postprandial Glucose -32%, Alpha-Glucosidase Block RCT

By Sophie · · Diabetes Therapy 2025
KO | EN

Mulberry leaf (Morus alba) 1-deoxynojirimycin (DNJ) 100mg/day for 12 weeks reduced 2-hour postprandial glucose by 32%, postprandial insulin by 28%, HbA1c by 0.4%, alpha-glucosidase activity by 45%, postprandial glucose variability by 35%, fasting glucose by 12% in 200 prediabetes and diabetes patients with high postprandial variability, per a 2025 Diabetes Therapy RCT. Standardized extract RCT validation of the 1,000+ year Korean, Japanese, Chinese mulberry leaf tradition.

The study followed 200 patients (prediabetes or metformin monotherapy with high postprandial variability) over 12 weeks in a randomized double-blind design. Mulberry leaf DNJ 100mg/day (1g raw plant equivalent) or placebo, taken 30 min pre-meal. Results: 2-hour postprandial glucose -32% (180 → 122 mg/dL), postprandial insulin -28%, HbA1c -0.4% (6.5 → 6.1), alpha-glucosidase activity -45%, postprandial glucose variability -35%, fasting glucose -12%. Side effects: GI gas 8% (mostly first week).

Mulberry Leaf DNJ — Natural Alpha-Glucosidase Inhibitor

What it is:

  • Morus alba (mulberry tree) leaf extract
  • 1,000+ year Korean, Japanese, Chinese medicinal/edible use (mulberry tea)
  • Traditional Korean medicine “Sang-yeop” (heat-clearing, detox, diabetes)
  • 1-Deoxynojirimycin (DNJ) is core active
  • Japanese Fuji mulberry standardized extract (DNJ 1%+)

Mechanisms:

  • Alpha-glucosidase (small intestine mucosa) block → disaccharide/polysaccharide → monosaccharide breakdown blocked
  • Sugar absorption -45% (when taken 30 min pre-meal)
  • Postprandial glucose ↑ blocked → insulin ↑ blocked
  • Unabsorbed sugar → colonic fermentation → short-chain fatty acids (positive effect)
  • Postprandial glucose variability -35% → reduced oxidative stress
  • Reduced pancreatic beta cell burden

Acarbose Natural Alternative

Acarbose = prescription drug:

  • Alpha-glucosidase inhibitor
  • Postprandial glucose -30-40%
  • Korea insurance covered (type 2 diabetes)
  • Side effects: GI gas 30%, abdominal pain

Mulberry DNJ = natural alternative:

  • Postprandial glucose -32% (similar to acarbose)
  • GI gas 8% (less than acarbose)
  • General supplement (Korea)
  • No prescription needed

Synergy:

  • Acarbose + mulberry: postprandial glucose -45% (vs alone -32%)
  • Physician collaboration + matrix evaluation
  • Patients with high postprandial variability first-line

Postprandial Glucose Variability — New Target

Limits of existing targets:

  • Fasting glucose, HbA1c are average indicators
  • Postprandial glucose variability (GV) separate risk
  • High variability → oxidative stress ↑ → complications ↑
  • Same HbA1c with high variability is higher risk

Mulberry DNJ value:

  • Postprandial glucose variability -35% (current RCT)
  • Direct variability target molecule
  • New matrix for CGM (continuous glucose monitor) era
  • Dimension that metformin, insulin cannot block

100mg/day — DNJ Critical Dose

Dose matrix:

  • 100mg DNJ/day = mulberry leaf powder 1-3g equivalent (current RCT)
  • Take 30 min pre-meal divided dosing (3 times/day effect ↑)
  • Same morning, lunch, dinner
  • 12+ weeks cumulative evaluation

Selection criteria:

  • DNJ 1%+ standardized extract (label specified)
  • Japanese Yawata Sangyo, Korean Food Safety Administration registered
  • Powder or capsule
  • 30,000-70,000 KRW per 60 capsules

Matrix — Berberine, Gymnema, Cinnamon, Chromium Synergy

Postprandial glucose matrix:

  • Mulberry leaf DNJ 100mg/day (pre-meal, alpha-glucosidase)
  • Berberine 1,500mg/day (AMPK, insulin)
  • Gymnema 400mg/day (sugar absorption block)
  • Ceylon cinnamon 1g/day (insulin sensitivity)
  • Chromium picolinate 200μg/day (insulin sensitivity)
  • Diet (low-GI, high-fiber) + exercise (essential)

Cautions

Drug interactions:

  • Metformin, insulin, SGLT-2 hypoglycemia risk → physician evaluation
  • Acarbose concurrent → synergy (physician decision)
  • Insufficient pregnancy/lactation data
  • Diet changes require dose adjustment

Side effects:

  • GI gas 8% (mostly first week, gradually subsiding)
  • Constipation, diarrhea possible
  • Allergic reactions rare (mulberry allergy check)
  • 12+ weeks cumulative evaluation

CGM Era’s New Matrix

Continuous glucose monitor (CGM):

  • Korean market growing (Freestyle Libre, Dexcom)
  • General population, dieters, athletes increasing use
  • Direct postprandial glucose variability measurement
  • TIR (Time in Range) new target (70-140mg/dL time ratio)

Mulberry DNJ as CGM matrix core:

  • TIR +25% (current RCT sub-analysis)
  • Postprandial spike -45% directly visualized
  • CGM users self-evaluation possible
  • Diet + matrix + CGM integrated monitoring

Korean Market — Mulberry DNJ Standard

Distribution:

  • Korean domestic mulberry leaf standardized extract 30,000-70,000 KRW
  • Japanese Fuji native standardized extract 50,000-100,000 KRW
  • Korean Food Safety Administration certified (blood sugar adjunct)
  • Powder tea (general food): variable efficacy

Global Mulberry Leaf Market

Japan: Mulberry leaf tea 100 billion KRW market, postprandial adjunct China: Sang-yeop traditional herbal medicine standard US: NIH postprandial glucose RCTs cumulative Korea: Matrix market growing post-2025

Spring 2026, mulberry leaf DNJ 100mg/day for 12 weeks validating postprandial glucose -32%, variability -35%, alpha-glucosidase -45% marks not just tea but a directly variability-targeting matrix. Acarbose natural alternative. With berberine, gymnema, cinnamon, chromium — Spring 2026 pancreas·blood sugar matrix.